Biogen and Eisai win Japan approval for at-home Leqembi as Alzheimer’s competition moves beyond efficacy
Japan has approved the Leqembi Pen for once-weekly at-home administration in early Alzheimer’s disease, potentially reducing infusion-center dependence while giving Biogen and Eisai another way to differentiate lecanemab from rival anti-amyloid therapies.
